SCHEMBL3340440

SCHEMBL3340440

COc1ccc(-c2csc(NNC(=O)c3ccncc3)n2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.61
KDM4E B2RXH2 6/20 0.61
LMNA P02545 3/20 0.61
HTT P42858 3/20 0.61
TDP1 Q9NUW8 3/20 0.61
MAPK1 P28482 2/20 0.61
ALDH1A1 P00352 5/20 0.60
GAA P10253 5/20 0.60
ADORA3 P0DMS8 1/20 0.60
ROCK1 Q13464 3/20 0.59
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
THRB P10828 1/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
ROCK2 O75116 2/20 0.57
RAB9A P51151 1/20 0.57
CSNK2A1 P68400 1/20 0.56
POLB P06746 1/20 0.55
PARP1 P09874 1/20 0.55
CA12 O43570 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3341186 0.89 MAPT (0.77) MAPTKDM4ELMNAHTTTDP1
SCHEMBL12301211 0.88 ADORA3 (0.76) MAPTKDM4ELMNAHTTMAPK1
SCHEMBL3341553 0.87 MAPT (0.74) MAPTKDM4ELMNAHTTTDP1
SCHEMBL1881014 0.84 ADORA3 (0.82) MAPTKDM4ELMNAHTTMAPK1
SCHEMBL3339116 0.84 MAPT (0.64) MAPTKDM4ELMNAHTTTDP1
SCHEMBL3338658 0.84 MAPT (0.71) MAPTKDM4ELMNAHTTTDP1
SCHEMBL3338134 0.84 KDM4E (0.85) MAPTKDM4ELMNAHTTTDP1
SCHEMBL3337373 0.79 PTGS2 (0.64) MAPTKDM4ELMNAHTTTDP1
SCHEMBL3338172 0.79 MEN1 (0.80) MAPTKDM4ELMNAHTTTDP1
SCHEMBL14527345 0.77 SMN1; SMN2 (0.63) MAPTLMNAMAPK1ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US claimed
US-8410152-B2 Thiazolhydrazides for treatment of neurodegenerative diseases MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E. V. (DE) 2013-04-02 US disclosed
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US disclosed
WO-2008052804-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES HTT, MAPT, SNCA MAPT 2/4885KDM4E 4489/4885LMNA 2315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.